The 2022 Horizon PrizeLink opens in a new window was awarded to Peter Sadler and his team "For pioneering work on catalysis of redox reactions in cancer cells by synthetic organometallic complexes".

Martin Wills (Warwick) recognised that some of his organometallic catalysts were similar to some of PJS's anticancer compounds and suggested a collaboration which has clearly been very successful. RJD's contribution was to provide computational underpinning in the form of structure and reactivity predictions.